The electronically-calculated Drug Resistance in Pneumonia (DRIP) score more accurately predicted the risk for drug-resistant pathogens in community-acquired pneumonia patients, according Chest data reported by Healio.
Researchers compared the impact of adding DRIP vs. healthcare-associated pneumonia criteria to the electronic decision tool on broad-spectrum antibiotic use, mortality, hospital stay and costs.
Using the DRIP score, researchers found there was a 7.2% reduction in absolute risk in administration of broad-spectrum antibiotics (40.1% vs 33%) as well as a reduction in the number of days of vancomycin therapy (287.3 per 1,000 patient-days vs. 238.8 per 1,000 patient-days).
